Both in Biotechnology
SAB Biotherapeutics vs X4 Pharmaceuticals
Over the past year SABS returned +65.1% and XFOR returned −13.4%; their daily moves had a correlation of 0.20.
SABS +65.1% XFOR −13.4%Growth of $1, one year, split-adjusted
| Metric | SABS | XFOR |
|---|---|---|
| Price | $3.22 | $2.90 |
| Market cap | $293.0M | $287.5M |
| Today | +0.16% | −3.81% |
| 1 month | −15.0% | −28.2% |
| 6 months | −14.8% | −27.3% |
| Year to date | −13.9% | −27.5% |
| 1 year | +60.2% | −16.2% |
| Revenue growth (YoY) | — | +346.3% |
| Gross margin | — | 81.6% |
| Net margin | — | −183.5% |
| P/E (TTM) | — | — |
| Price / sales | — | 18.1× |
| Net cash | $99.4M | $131.2M |
| Dividend yield | — | — |
| Volatility (60d) | 37.6% | 64.2% |
| Short % of float | 5.1% | 9.6% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).